Biotech Proper Is Overbought, Time To Look At Alternatives [View article]
Michael -
Thanks for the challenging comment. I'll say first that the negative sentiment of your comment is indicative of how many investors feel about biotech hardware, which is why it hasn't gone anywhere. If you have a subscription to Sentimentrader, you know that sentiment is a coveted contraindicator. Second, I don't expect anyone to turn $10K into $100K in three years. If that's the impression you got from my recommendations, then you're reading into it too much.
I will reiterate my basic thesis again. Biotech has gone way up and has little room for further capital gains. It's a logical assumption that related sectors that should profit from the success of biotech but have yet to do so, have a good chance of following that success rather than some unrelated sector.
Biotech consolidated and then took off. Sentiment is too bullish. There isn't much more money to be made there. Biotech hardware has been and is still moving sideways, and sentiment is bearish. There is a much better chance of making money there rather than in biotech proper.
Therapeutic Cancer Vaccines: From The Underwhelming To The Exciting [View article]
Stimuvax is currently being tested in phase III against lung cancer. The initial PIII trials in '09 referred to here were set up for breast cancer patients. See the "phase III trials" link in the Stimuvax section for more information.
NovaBay: Biotech, Pharma, And Profiting On FDA Induced Jumps [View article]
FDA approved weight loss drugs are not the only corner of the weight loss market. There are thousands of diets, training programs, herbal appetite suppressants, dieting agencies, nutritionists, all manner of things. The weight loss market is indeed saturated in this respect. Consumers are pulled in all these directions, not just FDA approved drugs. I think that is what the author had in mind.
Biotech Proper Is Overbought, Time To Look At Alternatives [View article]
Thanks for the challenging comment. I'll say first that the negative sentiment of your comment is indicative of how many investors feel about biotech hardware, which is why it hasn't gone anywhere. If you have a subscription to Sentimentrader, you know that sentiment is a coveted contraindicator. Second, I don't expect anyone to turn $10K into $100K in three years. If that's the impression you got from my recommendations, then you're reading into it too much.
I will reiterate my basic thesis again. Biotech has gone way up and has little room for further capital gains. It's a logical assumption that related sectors that should profit from the success of biotech but have yet to do so, have a good chance of following that success rather than some unrelated sector.
Biotech consolidated and then took off. Sentiment is too bullish. There isn't much more money to be made there. Biotech hardware has been and is still moving sideways, and sentiment is bearish. There is a much better chance of making money there rather than in biotech proper.
10x? I doubt it. But there will be gains.
Therapeutic Cancer Vaccines: From The Underwhelming To The Exciting [View article]
Thanks for the feedback.
NovaBay: Biotech, Pharma, And Profiting On FDA Induced Jumps [View article]